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Abstract
Introduction: In contrast to the global trend showing a decline in new HIV infections, the number reported in the World Health
Organization (WHO) region of Europe is increasing. Health systems are disparate, but even countries with free access to
screening and treatment observe continuing high rates of new infections in key populations, notably men who have sex with
men (MSM). Pre-exposure prophylaxis (PrEP) is only available in France. This commentary describes the European epidemics and
healthcare settings where PrEP could be delivered, how need might be estimated for MSM and the residual barriers to access.
Discussion: Health systems and government commitment to HIV prevention and care, both financial and political, differ
considerably between the countries that make up Europe. A common feature is that funds for prevention are a small fraction of
funds for care. Although care is generally good, access is limited in the middle-income countries of Eastern Europe and central
Asia, and only 19% of people living with HIV received antiretroviral therapy in 2014. It is challenging to motivate governments or
civil society to implement PrEP in the context of this unmet treatment need, which is driven by limited national health budgets
and diminishing assistance from foreign aid. The high-income countries of Western Europe have hesitated to embrace PrEP for
different reasons, initially due to key gaps in the evidence. Now that PrEP has been shown to be highly effective in European
MSM in two randomized controlled trials, it is clear that the major barrier is the cost of the drug which is still on patent,
although inadequate health systems and diminishing investment in civil society are also key challenges to overcome.
Conclusions: The momentum to implement PrEP in European countries is increasing and provides a welcome opportunity to
expand and improve clinical services and civil society support focused on HIV and related infections including other sexually
transmitted and blood-borne infections.
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Introduction
In contrast to sub-Saharan Africa, estimates of HIV incidence
have not decreased in the World Health Organization (WHO)
region of Europe. Indeed they increased, and in 2014 the
highest number and rate of HIV infections were reported
[1]. The majority (77%) were reported from the East (15
countries). Even though numbers appear ‘‘stable’’ in Western
Europe (23 countries), this disguises high and rising incidence
in subpopulations of men who have sex with men (MSM)
[2] confirmed in two recent studies [3,4]. The epidemic in
Eastern Europe differs substantially from the West; only 2%
of new cases are in MSM, and access to treatment remains
a major obstacle to infection control [2]. People who inject
drugs (PWID) accounted for 3 and 28% of new diagnoses in
Western and Eastern Europe respectively, in 2014. Although
outbreaks have been observed in the West and Centre (15
countries), for example in Greece and Romania, they have
been rapidly controlled by harm reduction interventions
including needle exchange and opiate substitution therapy
[5]. This commentary describes the European epidemics and
healthcare settings where PrEP could be delivered, how need
might be estimated for MSM and the residual barriers to
access.
European epidemic
In 2004, representatives of 53 countries that constitute
Europe as defined by the WHO, including the 31 countries
that make up the single market of the European Economic
Area, met in Dublin and issued a declaration of partnership
to fight HIV/AIDS in Europe and central Asia. Part of the
declaration was an agreement to monitor progress on the
33 actions to be taken, in alternate years from 2006. These
progress reports, together with routine national surveillance
data, enable the WHO and the European Centre for Disease
Prevention and Control (ECDC) to generate a picture of the
regional epidemics, the national responses which depend
to a substantial degree on the national economy and the
residual challenges.
In 2014, there were 142,197 new diagnoses made in 50 of
the 53 countries, the highest annual number since reporting
started in the 1980s [2]. Of these diagnoses, 56,945 were
officially reported by 49 countries to ECDC and a further 85,252
were reported by the Russian Federal Scientific and Metho-
dological Centre for Prevention and Control of AIDS. The
variation in epidemic patterns is considerable across the region
with the most striking differences among the 23 countries that
make up Western Europe and the 15 countries that make up
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Eastern Europe. The epidemic change in the West is most
apparent among MSM. There has been a sustained increase in
estimated incidence of HIV and other sexually transmitted
infections (STIs) in this population since 2005, even in
countries with good access to treatment and care [6,7]. During
the same period, new diagnoses due to the second most
common route, heterosexual transmission, declined. However,
this was not due to a decline in heterosexual HIV acquired
withinWestern Europe but rather the 52% decline in cases that
had acquired their HIV outside the region. Nearly half of those
living with HIV present with a CD4 count B350 at diagnosis,
and this underscores the need to expand and promote HIV
testing services to improve uptake of regular testing in key
populations and strengthen linkage to care [2]. In contrast to
the countries of Western Europe, the change in the epidemic
between 2005 and 2014 is most apparent in females in Eastern
Europe, where the two largest countries are Russia and
Ukraine. Rates in women have increased by 74% compared
with a 49% increase in cases of men. Although women are
more susceptible to HIV for biological and sociological reasons
(no independent income and domestic violence), this does not
entirely explain the gender difference, especially as a sub-
stantial proportion of new diagnoses in heterosexual menmay
be misclassified as MSM and PWID. The higher rates reported
in women in this region may represent the ‘‘second wave’’ of
infections from a predominantly male population of injecting
drug users.
It is important to recognize that the surveillance data do
not provide an accurate estimate of the incidence of HIV in
subpopulations. In the UK, where the mathematical models of
the epidemic are a good fit to the surveillance data, the
national estimate of incidence in MSM attending sexual
health clinics was 1.6 per 100 person years (PY) in 2014 [8],
whereas the observed incidence in the PROUD study
participants drawn from the same population was much
higher at 9 per 100 PY [3]. Each country has hot spots
(geographically) and sexual networks that facilitate HIV
transmission. In the IPERGAY trial, for example, HIV incidence
in the placebo arm among MSM reporting condomless sex
with two or more partners in the previous six months was
9.17 per 100 PY in Paris compared with 2.45 in other large
cities (Molina JMM, personal communication). Also, 45% of all
newly discovered infections in France in 2014 were diagnosed
in the Ile-de-France region, which accounts for only 18% of
the overall French population of 66M [9]. These data imply
that, even though risk behaviours may be similar, the risk of
acquiring HIV infection varies geographically, with MSM living
in Paris and the larger Ile-de-France region having a nearly
threefold increase in HIV risk acquisition.
The information is most limited for sex workers, trans
women, trans men and migrants. Where data do exist, it is
clear that the prevalence of HIV is higher than the general
population [911]. Migrant women account for one in four
new diagnoses in France each year but it is not entirely clear
where they acquired their HIV and, when in France, whether
this was from sex work, or from their partners who may be
having sex with men without considering themselves to be
gay, or from partners who migrated from countries with high
prevalence. Nonetheless, within these populations, the offer
of PrEP is likely to appeal most to individuals who recognize
their risk, as was the case in PROUD and IPERGAY.
Service organization
Public health services are highly variable across the region,
ranging from open access to free services for HIV and STI
testing and treatment through to access only with significant
copayments or in the worst-case scenario extremely limited
access to non-confidential and pejorative services. Healthcare
is funded by the public sector through tax and social insurance
contributions in most countries, with a small contribution
from private insurance schemes (B5%). In a few countries,
including Germany and the Netherlands, healthcare is deliv-
ered by the public sector but funded mainly through insurance
schemes and/or formal and informal copayments [12].
Regardless of the model, expenditure on health in the
European countries that belong to the Organization for
Economic Co-operation and Development (OECD), particularly
those in Southern Europe, is lagging behind other OECD
countries and has been static or shrinking over the last five
years, due to the economic crisis [13].
Community-based organizations do offer HIV/STI screening
in some settings, frequently tailored to key populations.
These services collaborate for post-exposure prophylaxis as




The two countries in which the PrEP trials were conducted,
France and England, have attempted to estimate the need for
PrEP among key populations. In the 2014 French report, there
were 6600 new diagnoses of HIV: 42% in MSM (an increase of
5% compared to 2013), 23% among women and 16% among
men born in foreign countries. Twenty-one per cent of those
from sub-Saharan Africa were thought to have acquired HIV in
France.This may be an underestimate, as the ANRS PARCOURS
study found that 35% had acquired HIV after migration to
France (30% of women and 44% of men) [14]. Hardship was
common among migrants from sub-Saharan Africa, with more
than 40% living for at least one yearwithout a residence permit
and more than 20% with no stable housing. Women who
reported hardship were also more likely to report casual and
transactional partners. This observation may help services to
identify heterosexuals who would benefit from PrEP.
Data from the UK are similar with 6151 new diagnoses
in 2014. Although the majority (3360) was in MSM, 1460
heterosexual HIV infections were estimated as acquired in the
UK by migrants living in the UK or by those born in the UK.
Unfortunately, it is not yet clear how to identify the hetero-
sexuals at risk who would benefit from PrEP. Late presentation
among heterosexuals remains unacceptably high and efforts to
increase testing in this population are a priority.
Having gathered robust evidence for clinical effectiveness
in two randomized controlled trials in MSM, it is possible to
identify the characteristics of MSM who would benefit from
PrEP. Policy makers have used this information to estimate
the likely size of each national PrEP programme to determine
the budget impact. In France (66 million inhabitants in 2013),
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the MSM population is estimated to be around 330,000
persons [15]. In a large anonymous cross-sectional survey
conducted in 2011 in France, 20.8% of HIV-negative MSM
reported no discernible risk reduction behaviour and can be
considered at high risk of HIV acquisition [16]. A seropreva-
lence survey in Paris found 17.7% of MSM to have HIV, so this
suggests that about 50,000MSM in Francemay need PrEP [17].
According to the most recent national UK survey of attitudes
to sex and lifestyles conducted between 2010 and 2012,
2.6% (95% CI 2.13%) of men aged 16 to 74 have had a same
sex experience in the preceding five years. Although the
majority self-identified as gay, 28% considered themselves to
be straight and 19% bisexual [18]. Applying 2.6% to the 2011
UK census estimate of 20 million men aged 15 to 64 suggests
that there are 500,000 MSM in this age group. The sexual
health clinic network sees 100,000 HIV-negative MSM at least
once each year. Behavioural data from clinic surveys (unpub-
lished data, Public Health England) suggest that half or more
have had anal sex without a condom in the preceding six
months. This generates a similar maximum number to France
(50,000) although not all of these individuals may want or
need PrEP, as a substantial proportion will be in a monoga-
mous relationship with a concordant negative partner or a
positive partner on treatment with undetectable viral load.
In the United States PrEP has been available since 2012.
Only 49,000 to 80,000 individuals have started PrEP in the
United States among an overall population of 323 million with
an estimated need among MSM of 492,000 (Grant R, personal
communication). Further, a substantial proportion of the
early adopters was women. Based on the US experience, a
target of 50,000 MSM seems highly aspirational for France
and the UK. If 50,000 MSM took PrEP for one year, the budget
impact for drug alone would be t150M in the region to sup-
port an IPERGAY regimen and almost double to support a
daily regimen.
For non-MSM populations, it is less clear who will come
forward to access PrEP, what their likely incidence would
be without PrEP and how effective PrEP will be. In England,
estimated HIV incidence in Black African heterosexuals that
access the sexual health clinics is higher than overall hetero-
sexuals (0.17% per year compared to 0.03% in 2012) but still
low. About 1000 heterosexual men and 1000 heterosexual
women accessed PEP in 2012, and the numbers were similar
in 2013.
Movement in the right direction
The French authorities approved Truvada† (TDF/FTC) under a
recommendation for temporary use, effective from 4 January
2016. Truvada is fully covered by the healthcare system but
visits and tests will be covered at the usual rate, which is
60% of costs reimbursed. This process is independent of the
European Medicines Agency (EMA), was initiated under
pressure from civil society and was supported by the Minister
of Health for France, who agreed to fully reimburse the costs
for drug.
Widespread concern about the possibility that PrEP would
lead to a decrease in condom use and precipitate an increase
in other STIs inspired the PROUD trial design to compare
immediate access to PrEP to a delayed access after 12 months.
There were differences in behaviour with a significantly
higher proportion of PrEP users reporting 10 or more partners
with whom they had had receptive anal sex without a condom
in the preceding 90 days (21% immediate PrEP compared
to 12% deferred) [3]. However, there were no differences in
the proportion who acquired other STIs. In reality, the rates
of other STIs have been increasing for the last decade, driven
largely by infections in HIV-positive MSM but accompanied
by a steady increase in syphilis, gonorrhoea and chlamydia in
HIV-negative MSM [6,19]. The introduction of PrEP offers
an opportunity to control STIs through regular asymptomatic
screening, prompt treatment, and active notification and
treatment of partners. Importantly, PROUD demonstrated
that the efficacy of PrEP was not undermined by the presence
of these other STIs.
The success of the two randomized trials and subsequent
implementation of demonstration projects in Amsterdam and
in Antwerp have strengthened the partnership between civil
society and themedical community in Europe, broadly through
the activities of the European AIDS Treatment Group and
the EuroPrEP collaboration. The partnership between EATG
members and the EuroPrEP clinicians started at the country
level around the trials, for example the role of AIDES in the
French IPERGAY trial, and the Community Engagement Group
that supported PROUD. To date, the European partnership has
been concentrated in the countries of Western Europe, but it
will be important to expand and support countries in Eastern
Europe and central Asia as they embark on demonstration
projects or national programmes. A common problem for
all countries is the cost of the drug which makes large-scale
national PrEP programmes look unaffordable. This is the
underlying reason that the PrEP policy has stalled in England
andWales, where the National Health Service is only willing to
contribute £2M to the early implementation activities. The
EuroPrEP collaboration wrote to Gilead Sciences, the sole source
of Truvada† for European governments, on 1 December 2015
with two requests: first that Gilead submit to the EMA as
regulatory approval is considered essential for national policy in
some countries, and second that they consider reducing the
price of drug. Gilead has now submitted to the EMA.While we
are not aware of any reductions in the cost of the drug, the
company is clearly willing to negotiate at the country level as
demonstrated by Portugal and Georgia, where hepatitis C
treatment is being fully implemented.
Residual barriers and solutions
A key challenge for Europe is to meet the needs of other
high-risk groups, particularly migrants, for whom the links
with community-based organizations and the healthcare
system are much lower than for MSM.
While those that purchase health care are concerned that
uptake will be higher than planned, advocates and clinicians
recognize the reality that many of those in need will not take
up the offer of PrEP, especially young MSM aged 15 to 24  a
group in whom the number of new diagnoses has more than
doubled since 2003. Their health-seeking behaviours differ
considerably from older MSM, and health promotion efforts,
as well as services, need to adapt and innovate to meet their
needs. An important modification to services will be to build
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on the partnerships developed during the trials and shift tasks
away from clinicians and hospitals towards community-based
organizations which are more acceptable venues for indivi-
duals who do not consider themselves to be ‘‘patients.’’
The two major components driving cost-effectiveness are
the price of drug and HIV incidence [20]. PrEP is cost saving
at the incidence rates reported in the two trials, but barely
cost-effective as a daily regimen when the national incidence
rates are applied over an 80-year time horizon [21]. The event-
driven, on-demand regimen used in IPERGAY and recom-
mended for MSM by the European AIDS Clinical Society [22],
utilized about half the amount of drug required to support
a daily regimen, equating to a 50% reduction in price. The
US Centre for Disease Control and Prevention [23] and WHO
[24] do not yet recommend this regimen, but guidelines are
likely to be revised as evidence gathers from the European
studies. Importantly, TDF/FTC could be available from generic
manufacturers in 2017 and European countries should
encourage manufacturers to prepare for large-scale demand
for this drug, which is also popular as a treatment option.
Assuming the issue of drug costs can be resolved, there are
additional requirements to implement a combination preven-
tion strategy incorporating PrEP. This includes raising aware-
ness of PrEP with information campaigns aimed at the
‘‘late majority and the laggards,’’ and building capacity to
deliver prevention and care in a more integrated service than
currently exists in most countries. This will require political
will from government, purchasers and providers of services
but could be done by strengthening partnerships and empow-
ering a broader range of providers to undertake screening with
minimal additional funding. Governments may need to see a
demonstration of these partnerships to be convinced that
it is easy to accommodate PrEP within existing reconfigured
services. Over the last few years, there has been diminishing
investment in civil society and this trend needs to be reversed
if we are to effectively raise awareness of PrEP and promote a
holistic approach to prevention, which starts with a HIV test.
Scaling up and normalizing HIV testing will be critical for
countries where HIV has spilled into the general population.
An important starting point for Europe is to strengthen the
role and scope of the European Centre for Disease Control
and Prevention. This organisation has the data, albeit limited,
and is best placed to advise individual countries on the
model of prevention and care to adopt.
Conclusions
There has never been a better time to advocate for
strengthening prevention services and increasing access for
key populations with increased risk of acquiring HIV and other
sexually transmitted and blood-borne infections. These po-
pulations are invariably vulnerable, with other health and
social care needs. Screening is at the core of this and services
need to increase throughput, taking advantage of innovations
in self-sampling, self-testing and community-based testing.
Governments should be confident of success. With political
will, the epidemic trends in Europe could be reversed.
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